A Phase Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

• Status: RECRUITING
• Trial end date: 2030-12-09

Summary

This is a Phase , randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; pembrolizumab; Trastuzumab; trastuzumab deruxtecan